ProShares Ultra Nasdaq Biotechnology (BIB) Declines 4.17% for Nov 10

November 10, 2018 - By Adrian Erickson

Nov 10 is a negative day so far for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) as the ETF is active during the day after losing 4.17% to hit $53.5 per share. The exchange traded fund has 305.89 million net assets and 3.46% volatility this month.

Over the course of the day 176,161 shares traded hands, as compared to an average volume of 178,310 over the last 30 days for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB).

The ETF is -20.64% of its 52-Week High and 23.83% of its low, and is currently having ATR of 2.02. This year’s performance is -1.46% while this quarter’s performance is -1.62%.

The ETF’s YTD performance is -10.54%, the 1 year is -7.32% and the 3 year is -9.21%.

The ETF’s average P/E ratio is 14.45, the price to book is 3.53, the price to sales is 4.76 and the price to cashflow is 12.72. It was started on 04/09/2010. The fund’s top holdings are: Nasdaq Biotechnology Index Swap Deutsche Bank Ag for 33.14% of assets, Nasdaq Biotechnology Index Swap Ubs Ag for 22.06%, Ishares Biotech (Ibb) Swap Bank Of America Na for 17.48%, Nasdaq Biotechnology Index Swap Bank Of America Na for 13.59%, Nasdaq Biotechnology Index Swap Credit Suisse International for 9.26%, Amgen Inc for 8.23%, Gilead Sciences Inc for 7.68%, Nasdaq Biotechnology Index Swap Citibank Na for 7.55%, Biogen Inc for 7.34%, Celgene Corp for 6.20%. The ETF sector weights are: Basic Materials 0.00%, Consumer Cyclical 0.00%, Financial Services 0.00%, Realestate 0.00%, Consumer Defensive 0.06%, Healthcare 99.92%, Utilities 0.00%, Communication Services 0.00%, Energy 0.00%, Industrials 0.00%, Technology 0.02%. The ETF currently as yield.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>